Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Medulloblastoma | 31 | 2022 | 658 | 7.080 |
Why?
|
Cerebellar Neoplasms | 28 | 2022 | 571 | 6.750 |
Why?
|
Ependymoma | 17 | 2024 | 310 | 5.280 |
Why?
|
Brain Neoplasms | 40 | 2024 | 9071 | 3.190 |
Why?
|
Rhabdomyosarcoma | 12 | 2024 | 354 | 2.630 |
Why?
|
Radiotherapy, Intensity-Modulated | 16 | 2022 | 784 | 2.600 |
Why?
|
Photons | 14 | 2024 | 572 | 2.440 |
Why?
|
Radiotherapy Dosage | 40 | 2024 | 2865 | 2.040 |
Why?
|
Protons | 18 | 2024 | 1073 | 1.870 |
Why?
|
Brain Stem | 7 | 2024 | 853 | 1.760 |
Why?
|
Central Nervous System Neoplasms | 11 | 2023 | 916 | 1.640 |
Why?
|
Rhabdoid Tumor | 4 | 2023 | 209 | 1.520 |
Why?
|
Organs at Risk | 13 | 2023 | 352 | 1.510 |
Why?
|
Cranial Irradiation | 8 | 2022 | 385 | 1.440 |
Why?
|
Teratoma | 4 | 2023 | 401 | 1.430 |
Why?
|
Radiation Injuries | 12 | 2021 | 1181 | 1.410 |
Why?
|
Radiotherapy | 14 | 2023 | 1494 | 1.380 |
Why?
|
Spinal Cord Neoplasms | 3 | 2023 | 258 | 1.280 |
Why?
|
Child | 112 | 2024 | 80564 | 1.270 |
Why?
|
Infratentorial Neoplasms | 5 | 2018 | 94 | 1.250 |
Why?
|
Child, Preschool | 80 | 2024 | 42500 | 1.240 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 17 | 2022 | 1643 | 1.090 |
Why?
|
Neoplasms, Radiation-Induced | 7 | 2015 | 540 | 1.010 |
Why?
|
Adolescent | 84 | 2024 | 88835 | 0.920 |
Why?
|
Neoplasms, Second Primary | 9 | 2020 | 1050 | 0.790 |
Why?
|
Infant | 42 | 2024 | 36386 | 0.790 |
Why?
|
Neuroectodermal Tumors, Primitive | 2 | 2020 | 135 | 0.740 |
Why?
|
Registries | 10 | 2024 | 8297 | 0.710 |
Why?
|
Neoplasms | 17 | 2022 | 22340 | 0.700 |
Why?
|
Meningeal Neoplasms | 5 | 2021 | 1252 | 0.700 |
Why?
|
Neoplasm Recurrence, Local | 12 | 2024 | 9373 | 0.690 |
Why?
|
Rhabdomyosarcoma, Embryonal | 3 | 2017 | 97 | 0.670 |
Why?
|
Cognition | 9 | 2021 | 7049 | 0.640 |
Why?
|
Young Adult | 48 | 2024 | 59889 | 0.640 |
Why?
|
Glioma | 6 | 2020 | 3493 | 0.620 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 5 | 2021 | 480 | 0.620 |
Why?
|
Lymphopenia | 1 | 2021 | 297 | 0.600 |
Why?
|
Radiotherapy, Conformal | 8 | 2020 | 533 | 0.600 |
Why?
|
Hearing Loss | 2 | 2023 | 784 | 0.590 |
Why?
|
Pituitary Gland | 2 | 2018 | 631 | 0.590 |
Why?
|
Intelligence | 3 | 2018 | 923 | 0.580 |
Why?
|
Carboplatin | 1 | 2021 | 789 | 0.580 |
Why?
|
Radiation Oncology | 3 | 2018 | 569 | 0.570 |
Why?
|
Wechsler Scales | 1 | 2018 | 255 | 0.570 |
Why?
|
Cochlea | 1 | 2023 | 847 | 0.550 |
Why?
|
Minors | 1 | 2017 | 59 | 0.550 |
Why?
|
Esthesioneuroblastoma, Olfactory | 2 | 2015 | 57 | 0.540 |
Why?
|
Humans | 155 | 2024 | 765968 | 0.530 |
Why?
|
Societies, Scientific | 1 | 2017 | 221 | 0.530 |
Why?
|
Disease-Free Survival | 16 | 2022 | 6832 | 0.530 |
Why?
|
Relative Biological Effectiveness | 9 | 2021 | 299 | 0.510 |
Why?
|
Radiotherapy, Adjuvant | 6 | 2024 | 1776 | 0.500 |
Why?
|
Craniopharyngioma | 5 | 2023 | 276 | 0.490 |
Why?
|
Male | 101 | 2024 | 363698 | 0.490 |
Why?
|
Endocrine System | 1 | 2015 | 111 | 0.470 |
Why?
|
Nasal Cavity | 2 | 2015 | 307 | 0.470 |
Why?
|
Nose Neoplasms | 2 | 2015 | 249 | 0.470 |
Why?
|
Dose-Response Relationship, Radiation | 3 | 2024 | 869 | 0.460 |
Why?
|
Female | 96 | 2024 | 396112 | 0.450 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 15 | 2021 | 11868 | 0.450 |
Why?
|
Combined Modality Therapy | 16 | 2023 | 8529 | 0.450 |
Why?
|
Lymphoma | 2 | 2020 | 1897 | 0.440 |
Why?
|
Pelvic Neoplasms | 2 | 2015 | 247 | 0.430 |
Why?
|
Thoracic Neoplasms | 2 | 2015 | 267 | 0.420 |
Why?
|
Osteoarthropathy, Secondary Hypertrophic | 1 | 2012 | 13 | 0.420 |
Why?
|
Hypothalamus | 1 | 2018 | 993 | 0.420 |
Why?
|
Databases, Factual | 3 | 2024 | 8067 | 0.410 |
Why?
|
Orbital Neoplasms | 3 | 2017 | 223 | 0.400 |
Why?
|
Radiation Tolerance | 1 | 2014 | 475 | 0.390 |
Why?
|
Leukemia | 2 | 2019 | 1522 | 0.390 |
Why?
|
Bone Neoplasms | 5 | 2018 | 2567 | 0.390 |
Why?
|
Survivors | 6 | 2020 | 2372 | 0.370 |
Why?
|
Follow-Up Studies | 23 | 2024 | 39193 | 0.360 |
Why?
|
Head and Neck Neoplasms | 5 | 2019 | 2921 | 0.360 |
Why?
|
Skull Base Neoplasms | 1 | 2014 | 276 | 0.360 |
Why?
|
Pituitary Neoplasms | 5 | 2023 | 1321 | 0.360 |
Why?
|
Informed Consent | 1 | 2017 | 1010 | 0.360 |
Why?
|
Age Factors | 9 | 2023 | 18380 | 0.350 |
Why?
|
Terminology as Topic | 1 | 2017 | 1534 | 0.350 |
Why?
|
Data Collection | 1 | 2019 | 3318 | 0.350 |
Why?
|
Alopecia | 1 | 2014 | 414 | 0.340 |
Why?
|
Spinal Neoplasms | 3 | 2014 | 708 | 0.340 |
Why?
|
Quality of Life | 10 | 2023 | 13462 | 0.330 |
Why?
|
Dinoprostone | 1 | 2012 | 591 | 0.330 |
Why?
|
Hodgkin Disease | 6 | 2021 | 1383 | 0.330 |
Why?
|
Treatment Outcome | 31 | 2021 | 65188 | 0.320 |
Why?
|
Retrospective Studies | 32 | 2024 | 81514 | 0.320 |
Why?
|
Myositis | 1 | 2011 | 270 | 0.300 |
Why?
|
Vincristine | 7 | 2020 | 1039 | 0.300 |
Why?
|
Pelvic Bones | 2 | 2010 | 274 | 0.300 |
Why?
|
Radiometry | 3 | 2018 | 804 | 0.290 |
Why?
|
Prospective Studies | 14 | 2024 | 54802 | 0.290 |
Why?
|
Creatine Kinase, MB Form | 1 | 2008 | 202 | 0.290 |
Why?
|
Hippocampus | 4 | 2023 | 3775 | 0.280 |
Why?
|
Kaplan-Meier Estimate | 6 | 2024 | 6499 | 0.270 |
Why?
|
Survival Rate | 10 | 2024 | 12795 | 0.270 |
Why?
|
Scattering, Radiation | 3 | 2017 | 482 | 0.270 |
Why?
|
Spinal Cord | 3 | 2021 | 1784 | 0.250 |
Why?
|
Germinoma | 4 | 2021 | 124 | 0.250 |
Why?
|
Endocrine System Diseases | 3 | 2018 | 243 | 0.250 |
Why?
|
Treatment Failure | 5 | 2019 | 2652 | 0.250 |
Why?
|
Thymus Neoplasms | 1 | 2008 | 270 | 0.250 |
Why?
|
Clinical Trials as Topic | 2 | 2017 | 8041 | 0.230 |
Why?
|
Pediatrics | 3 | 2018 | 3606 | 0.230 |
Why?
|
Brain Stem Neoplasms | 2 | 2018 | 192 | 0.230 |
Why?
|
Cyclophosphamide | 6 | 2021 | 2228 | 0.220 |
Why?
|
Supratentorial Neoplasms | 3 | 2013 | 153 | 0.220 |
Why?
|
Analysis of Variance | 3 | 2018 | 6203 | 0.220 |
Why?
|
Urinary Bladder Neoplasms | 2 | 2019 | 2176 | 0.220 |
Why?
|
Prognosis | 13 | 2024 | 29922 | 0.220 |
Why?
|
Etoposide | 4 | 2015 | 636 | 0.210 |
Why?
|
Perineum | 1 | 2024 | 213 | 0.210 |
Why?
|
Troponin T | 1 | 2008 | 785 | 0.210 |
Why?
|
Multicenter Studies as Topic | 2 | 2019 | 1731 | 0.210 |
Why?
|
Tumor Burden | 5 | 2021 | 1885 | 0.200 |
Why?
|
Executive Function | 2 | 2024 | 1391 | 0.200 |
Why?
|
Astrocytoma | 2 | 2019 | 772 | 0.200 |
Why?
|
Neuroblastoma | 3 | 2024 | 1263 | 0.200 |
Why?
|
Linear Energy Transfer | 4 | 2018 | 147 | 0.200 |
Why?
|
Lymphatic Irradiation | 2 | 2021 | 110 | 0.200 |
Why?
|
Cohort Studies | 12 | 2024 | 41649 | 0.190 |
Why?
|
Posterior Leukoencephalopathy Syndrome | 1 | 2022 | 49 | 0.190 |
Why?
|
Olfaction Disorders | 1 | 2024 | 223 | 0.190 |
Why?
|
Retinoblastoma | 2 | 2014 | 316 | 0.180 |
Why?
|
Esophageal Neoplasms | 2 | 2009 | 1661 | 0.180 |
Why?
|
Health Services Accessibility | 1 | 2019 | 5508 | 0.180 |
Why?
|
Confidence Intervals | 2 | 2017 | 2910 | 0.180 |
Why?
|
Osteolysis, Essential | 2 | 2013 | 30 | 0.180 |
Why?
|
Anus Neoplasms | 1 | 2024 | 336 | 0.170 |
Why?
|
Adult | 31 | 2024 | 223044 | 0.170 |
Why?
|
Doxorubicin | 5 | 2021 | 2230 | 0.170 |
Why?
|
Risk Assessment | 8 | 2021 | 24282 | 0.170 |
Why?
|
Sarcoma | 4 | 2021 | 1802 | 0.170 |
Why?
|
National Health Programs | 1 | 2023 | 443 | 0.170 |
Why?
|
Radiation Pneumonitis | 1 | 2020 | 98 | 0.170 |
Why?
|
Dactinomycin | 4 | 2019 | 304 | 0.160 |
Why?
|
Mutism | 1 | 2019 | 27 | 0.160 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2008 | 1736 | 0.160 |
Why?
|
Monte Carlo Method | 5 | 2017 | 1238 | 0.160 |
Why?
|
Osteosarcoma | 2 | 2018 | 909 | 0.160 |
Why?
|
Mediastinum | 1 | 2020 | 271 | 0.160 |
Why?
|
Lymphocyte Count | 1 | 2021 | 790 | 0.150 |
Why?
|
Lung Neoplasms | 4 | 2015 | 13451 | 0.150 |
Why?
|
International Cooperation | 3 | 2019 | 1432 | 0.150 |
Why?
|
Enterocolitis, Necrotizing | 1 | 2022 | 328 | 0.150 |
Why?
|
Time Factors | 9 | 2021 | 40065 | 0.150 |
Why?
|
Radiation Dosage | 5 | 2021 | 1944 | 0.150 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2023 | 1151 | 0.150 |
Why?
|
Neurocytoma | 1 | 2018 | 28 | 0.150 |
Why?
|
Choroid Plexus Neoplasms | 1 | 2017 | 38 | 0.140 |
Why?
|
Hypothyroidism | 1 | 2022 | 667 | 0.140 |
Why?
|
Cerebellar Diseases | 1 | 2019 | 226 | 0.140 |
Why?
|
Spine | 2 | 2017 | 1128 | 0.140 |
Why?
|
Fetal Diseases | 1 | 2022 | 914 | 0.140 |
Why?
|
Infant, Newborn, Diseases | 1 | 2022 | 587 | 0.140 |
Why?
|
Postoperative Period | 2 | 2019 | 1816 | 0.130 |
Why?
|
Hematologic Diseases | 1 | 2020 | 500 | 0.130 |
Why?
|
Li-Fraumeni Syndrome | 1 | 2017 | 116 | 0.130 |
Why?
|
Recurrence | 4 | 2023 | 8501 | 0.130 |
Why?
|
Disease Progression | 5 | 2021 | 13632 | 0.130 |
Why?
|
Neoplasm Staging | 6 | 2016 | 11206 | 0.130 |
Why?
|
Adenocarcinoma | 2 | 2012 | 6364 | 0.130 |
Why?
|
Retroperitoneal Neoplasms | 1 | 2019 | 335 | 0.130 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2018 | 639 | 0.130 |
Why?
|
Peptide Fragments | 1 | 2008 | 5125 | 0.120 |
Why?
|
Moyamoya Disease | 2 | 2021 | 273 | 0.120 |
Why?
|
Radiation, Ionizing | 1 | 2015 | 249 | 0.120 |
Why?
|
Models, Nursing | 1 | 2015 | 46 | 0.120 |
Why?
|
Topotecan | 1 | 2015 | 130 | 0.120 |
Why?
|
Cerebellum | 2 | 2019 | 1518 | 0.120 |
Why?
|
Delphi Technique | 3 | 2023 | 893 | 0.110 |
Why?
|
Prostatic Neoplasms | 2 | 2010 | 11083 | 0.110 |
Why?
|
Necrosis | 2 | 2018 | 1617 | 0.110 |
Why?
|
Optic Chiasm | 1 | 2014 | 88 | 0.110 |
Why?
|
Neuropsychological Tests | 5 | 2024 | 7123 | 0.110 |
Why?
|
Reference Standards | 1 | 2017 | 1013 | 0.110 |
Why?
|
Magnetic Resonance Imaging | 10 | 2017 | 36532 | 0.110 |
Why?
|
Cisplatin | 3 | 2015 | 1658 | 0.110 |
Why?
|
Growth Plate | 2 | 2017 | 273 | 0.110 |
Why?
|
Pituitary Gland, Posterior | 1 | 2013 | 41 | 0.110 |
Why?
|
Ifosfamide | 2 | 2021 | 233 | 0.110 |
Why?
|
Infant, Newborn | 8 | 2022 | 26346 | 0.110 |
Why?
|
Advisory Committees | 1 | 2017 | 796 | 0.110 |
Why?
|
Soft Tissue Neoplasms | 2 | 2021 | 1165 | 0.110 |
Why?
|
Prostate-Specific Antigen | 1 | 2002 | 2464 | 0.100 |
Why?
|
Neoplasms, Multiple Primary | 2 | 2014 | 587 | 0.100 |
Why?
|
Nausea | 3 | 2024 | 680 | 0.100 |
Why?
|
Optic Nerve Glioma | 1 | 2012 | 32 | 0.100 |
Why?
|
Parents | 2 | 2018 | 3592 | 0.100 |
Why?
|
Retinal Neoplasms | 1 | 2014 | 147 | 0.100 |
Why?
|
Memory, Short-Term | 2 | 2017 | 1003 | 0.100 |
Why?
|
Vomiting | 3 | 2024 | 647 | 0.100 |
Why?
|
Pineal Gland | 1 | 2013 | 153 | 0.100 |
Why?
|
Meningioma | 1 | 2021 | 1221 | 0.100 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2020 | 2024 | 0.100 |
Why?
|
Sex Factors | 2 | 2016 | 10603 | 0.090 |
Why?
|
Risk Factors | 8 | 2023 | 74840 | 0.090 |
Why?
|
Radiodermatitis | 1 | 2011 | 58 | 0.090 |
Why?
|
SEER Program | 2 | 2013 | 1446 | 0.090 |
Why?
|
Adaptation, Physiological | 1 | 2018 | 1308 | 0.090 |
Why?
|
Medical Informatics | 1 | 2018 | 745 | 0.090 |
Why?
|
Heart Neoplasms | 1 | 2015 | 375 | 0.090 |
Why?
|
Quality-Adjusted Life Years | 2 | 2015 | 1737 | 0.090 |
Why?
|
Rhabdomyosarcoma, Alveolar | 1 | 2011 | 41 | 0.090 |
Why?
|
Cerebral Cortex | 1 | 2007 | 5767 | 0.090 |
Why?
|
Memory Disorders | 1 | 2018 | 1194 | 0.090 |
Why?
|
Incidence | 6 | 2017 | 21480 | 0.090 |
Why?
|
Comprehension | 1 | 2015 | 638 | 0.080 |
Why?
|
Cost Savings | 1 | 2015 | 904 | 0.080 |
Why?
|
Delayed Diagnosis | 1 | 2013 | 452 | 0.080 |
Why?
|
Disease Management | 1 | 2020 | 2535 | 0.080 |
Why?
|
United States | 8 | 2021 | 72903 | 0.080 |
Why?
|
Biopsy | 2 | 2019 | 6763 | 0.080 |
Why?
|
Femur Head | 1 | 2010 | 295 | 0.080 |
Why?
|
Myelodysplastic Syndromes | 1 | 2018 | 1404 | 0.070 |
Why?
|
Self Report | 1 | 2019 | 3770 | 0.070 |
Why?
|
Nelson Syndrome | 1 | 2007 | 20 | 0.070 |
Why?
|
Histones | 1 | 2018 | 2584 | 0.070 |
Why?
|
Risk | 3 | 2019 | 9591 | 0.070 |
Why?
|
Neoplasm Invasiveness | 1 | 2016 | 3602 | 0.070 |
Why?
|
Apoptosis | 1 | 2023 | 9514 | 0.070 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 3251 | 0.070 |
Why?
|
Central Nervous System Cysts | 1 | 2007 | 56 | 0.070 |
Why?
|
Consensus | 3 | 2023 | 3202 | 0.070 |
Why?
|
Brain | 5 | 2019 | 27171 | 0.070 |
Why?
|
Testis | 1 | 2010 | 780 | 0.070 |
Why?
|
Lymphangiosarcoma | 1 | 2006 | 14 | 0.070 |
Why?
|
DNA, Neoplasm | 1 | 2012 | 1742 | 0.070 |
Why?
|
Middle Aged | 16 | 2022 | 223009 | 0.070 |
Why?
|
Temporal Lobe | 1 | 2014 | 1714 | 0.070 |
Why?
|
Carcinoma | 1 | 2017 | 2312 | 0.060 |
Why?
|
Central Nervous System | 1 | 2013 | 1341 | 0.060 |
Why?
|
Inflammation Mediators | 1 | 2015 | 1884 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-sis | 1 | 2006 | 254 | 0.060 |
Why?
|
Cognition Disorders | 1 | 2019 | 3967 | 0.060 |
Why?
|
Lens, Crystalline | 1 | 2007 | 387 | 0.060 |
Why?
|
Pituitary ACTH Hypersecretion | 1 | 2007 | 181 | 0.060 |
Why?
|
Massachusetts | 3 | 2018 | 8875 | 0.060 |
Why?
|
Cancer Care Facilities | 2 | 2018 | 426 | 0.060 |
Why?
|
Positron-Emission Tomography | 1 | 2021 | 6547 | 0.060 |
Why?
|
Urinary Bladder | 1 | 2010 | 1154 | 0.060 |
Why?
|
Cysts | 1 | 2009 | 684 | 0.050 |
Why?
|
Software | 1 | 2017 | 4462 | 0.050 |
Why?
|
Proportional Hazards Models | 2 | 2015 | 12509 | 0.050 |
Why?
|
Survival Analysis | 1 | 2016 | 10070 | 0.050 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2008 | 451 | 0.050 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2013 | 3537 | 0.050 |
Why?
|
Respiration | 1 | 2009 | 1653 | 0.050 |
Why?
|
bcl-2-Associated X Protein | 1 | 2023 | 283 | 0.050 |
Why?
|
Movement | 1 | 2009 | 1462 | 0.050 |
Why?
|
Drug Administration Schedule | 2 | 2013 | 4850 | 0.050 |
Why?
|
Family | 1 | 2012 | 3209 | 0.050 |
Why?
|
Sequence Analysis, DNA | 1 | 2012 | 4772 | 0.050 |
Why?
|
Breast Neoplasms | 2 | 2008 | 21056 | 0.040 |
Why?
|
Infusions, Intra-Arterial | 1 | 2021 | 218 | 0.040 |
Why?
|
Physicians | 1 | 2018 | 4588 | 0.040 |
Why?
|
Stroke | 1 | 2022 | 9747 | 0.040 |
Why?
|
Models, Economic | 2 | 2015 | 716 | 0.040 |
Why?
|
Bone Marrow | 1 | 2010 | 2921 | 0.040 |
Why?
|
Blood Cell Count | 1 | 2020 | 405 | 0.040 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2012 | 3655 | 0.040 |
Why?
|
Mutation | 3 | 2023 | 30198 | 0.040 |
Why?
|
Australia | 1 | 2023 | 1258 | 0.040 |
Why?
|
Neoplasm Metastasis | 1 | 2010 | 4893 | 0.040 |
Why?
|
Thalidomide | 1 | 2005 | 886 | 0.040 |
Why?
|
Spinal Cord Injuries | 1 | 2007 | 927 | 0.040 |
Why?
|
Cross-Sectional Studies | 2 | 2024 | 26318 | 0.040 |
Why?
|
Thyrotropin | 1 | 2022 | 841 | 0.040 |
Why?
|
Radiography | 3 | 2015 | 6919 | 0.040 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2006 | 1376 | 0.040 |
Why?
|
Calcinosis | 1 | 2007 | 1479 | 0.040 |
Why?
|
Cost-Benefit Analysis | 3 | 2018 | 5526 | 0.040 |
Why?
|
Cell Death | 1 | 2023 | 1679 | 0.040 |
Why?
|
Radiosurgery | 1 | 2007 | 1328 | 0.040 |
Why?
|
Fatigue | 2 | 2021 | 1549 | 0.040 |
Why?
|
Aged, 80 and over | 5 | 2018 | 59489 | 0.040 |
Why?
|
Growth Disorders | 1 | 2022 | 633 | 0.040 |
Why?
|
Aged | 9 | 2023 | 171117 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 5 | 2017 | 20659 | 0.030 |
Why?
|
Texas | 1 | 2018 | 410 | 0.030 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2006 | 1560 | 0.030 |
Why?
|
History, Ancient | 1 | 2017 | 213 | 0.030 |
Why?
|
Florida | 1 | 2018 | 416 | 0.030 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2020 | 616 | 0.030 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2018 | 299 | 0.030 |
Why?
|
Stress, Psychological | 1 | 2012 | 4533 | 0.030 |
Why?
|
Psychosocial Deprivation | 1 | 1976 | 101 | 0.030 |
Why?
|
Brain Injuries | 1 | 2007 | 2060 | 0.030 |
Why?
|
Normal Distribution | 1 | 2015 | 267 | 0.030 |
Why?
|
Genes, p53 | 1 | 2017 | 711 | 0.030 |
Why?
|
Evidence-Based Medicine | 1 | 2007 | 3685 | 0.030 |
Why?
|
Testicular Neoplasms | 1 | 2021 | 786 | 0.030 |
Why?
|
Angiogenesis Inhibitors | 1 | 2005 | 2056 | 0.030 |
Why?
|
Wnt Proteins | 1 | 2018 | 722 | 0.030 |
Why?
|
Extremities | 1 | 2019 | 869 | 0.030 |
Why?
|
Sirolimus | 1 | 2021 | 1545 | 0.030 |
Why?
|
Hedgehog Proteins | 1 | 2018 | 774 | 0.030 |
Why?
|
Vision Disorders | 1 | 2021 | 1087 | 0.030 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2012 | 5389 | 0.030 |
Why?
|
Universities | 1 | 2018 | 998 | 0.030 |
Why?
|
Uncertainty | 1 | 2018 | 761 | 0.030 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2023 | 2942 | 0.030 |
Why?
|
Headache | 1 | 2021 | 1259 | 0.030 |
Why?
|
Statistics, Nonparametric | 1 | 2018 | 2844 | 0.030 |
Why?
|
alpha-Fetoproteins | 1 | 2013 | 226 | 0.030 |
Why?
|
Nursing Methodology Research | 1 | 2012 | 63 | 0.020 |
Why?
|
Rare Diseases | 1 | 2018 | 635 | 0.020 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2005 | 2329 | 0.020 |
Why?
|
Community Health Services | 1 | 1976 | 657 | 0.020 |
Why?
|
Chorionic Gonadotropin | 1 | 2013 | 457 | 0.020 |
Why?
|
Radiopharmaceuticals | 1 | 2020 | 2699 | 0.020 |
Why?
|
Esophagus | 1 | 2017 | 1037 | 0.020 |
Why?
|
Vinblastine | 1 | 2012 | 483 | 0.020 |
Why?
|
Aspirin | 1 | 2022 | 3134 | 0.020 |
Why?
|
Intestine, Small | 1 | 2017 | 1214 | 0.020 |
Why?
|
Longitudinal Studies | 2 | 2019 | 14751 | 0.020 |
Why?
|
Behavior Therapy | 1 | 1976 | 884 | 0.020 |
Why?
|
Thyroid Gland | 1 | 2017 | 1180 | 0.020 |
Why?
|
Bone Resorption | 1 | 2013 | 717 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2021 | 2895 | 0.020 |
Why?
|
Cervical Vertebrae | 1 | 2015 | 974 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 2017 | 1884 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2002 | 12056 | 0.020 |
Why?
|
Liver Neoplasms | 1 | 2005 | 4353 | 0.020 |
Why?
|
Memory | 1 | 2018 | 2190 | 0.020 |
Why?
|
Signal Transduction | 2 | 2023 | 23601 | 0.020 |
Why?
|
Prednisone | 1 | 2012 | 1565 | 0.020 |
Why?
|
World Health Organization | 1 | 2013 | 1328 | 0.020 |
Why?
|
Hearing Loss, Sensorineural | 1 | 2013 | 781 | 0.020 |
Why?
|
Neutropenia | 1 | 2012 | 893 | 0.020 |
Why?
|
Body Height | 1 | 2013 | 1562 | 0.020 |
Why?
|
Nose Diseases | 1 | 2007 | 79 | 0.020 |
Why?
|
Neoplasm, Residual | 1 | 2011 | 1009 | 0.020 |
Why?
|
Chylothorax | 1 | 2006 | 83 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2017 | 5302 | 0.020 |
Why?
|
Fibroma | 1 | 2007 | 197 | 0.020 |
Why?
|
Methotrexate | 1 | 2012 | 1722 | 0.020 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2015 | 3672 | 0.020 |
Why?
|
Neuralgia | 1 | 2012 | 625 | 0.020 |
Why?
|
Pilot Projects | 1 | 2018 | 8733 | 0.020 |
Why?
|
Visual Acuity | 1 | 2014 | 2708 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2012 | 6069 | 0.010 |
Why?
|
Cause of Death | 1 | 2013 | 3708 | 0.010 |
Why?
|
Maximum Tolerated Dose | 1 | 2005 | 898 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2019 | 10383 | 0.010 |
Why?
|
Fatal Outcome | 1 | 2006 | 1831 | 0.010 |
Why?
|
Reference Values | 1 | 2009 | 4908 | 0.010 |
Why?
|
Remission Induction | 1 | 2007 | 2411 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 2018 | 9249 | 0.010 |
Why?
|
Kidney | 1 | 2017 | 7066 | 0.010 |
Why?
|
Kidney Neoplasms | 1 | 2018 | 4274 | 0.010 |
Why?
|
Liver | 1 | 2017 | 7562 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2018 | 7425 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2013 | 11022 | 0.010 |
Why?
|
Computer Simulation | 1 | 2013 | 6255 | 0.010 |
Why?
|
Hydrocortisone | 1 | 2007 | 1827 | 0.010 |
Why?
|
Antineoplastic Agents | 2 | 2013 | 13648 | 0.010 |
Why?
|
Toilet Training | 1 | 1976 | 18 | 0.010 |
Why?
|
Mice | 1 | 2023 | 81819 | 0.010 |
Why?
|
Imitative Behavior | 1 | 1976 | 35 | 0.010 |
Why?
|
Hyperkinesis | 1 | 1976 | 88 | 0.010 |
Why?
|
Personality Development | 1 | 1976 | 242 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2012 | 17075 | 0.010 |
Why?
|
Intelligence Tests | 1 | 1976 | 504 | 0.010 |
Why?
|
Verbal Behavior | 1 | 1976 | 328 | 0.010 |
Why?
|
Evaluation Studies as Topic | 1 | 1976 | 1600 | 0.010 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2009 | 4044 | 0.010 |
Why?
|
Comorbidity | 1 | 2008 | 10563 | 0.010 |
Why?
|
Social Isolation | 1 | 1976 | 366 | 0.010 |
Why?
|
Motor Skills | 1 | 1976 | 516 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2007 | 12976 | 0.010 |
Why?
|
Animals | 1 | 2023 | 168764 | 0.010 |
Why?
|
Social Behavior | 1 | 1976 | 1146 | 0.010 |
Why?
|